	Application No.	Applicant(s)
	09/806,823	FURITSU ET AL.
Notice of Allowability	Examiner	Art Unit
	James M Spear	1615
The MAILING DATE of this communication apper claims being allowable, PROSECUTION ON THE MERITS IS rewith (or previously mailed), a Notice of Allowance (PTOL-85) DTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI the Office or upon petition by the applicant. See 37 CFR 1.313	ears on the cover sheet with the (OR REMAINS) CLOSED in this or other appropriate communica GHTS. This application is subjection	s application. If not included ation will be mailed in due course. THIS
 ☑ This communication is responsive to <u>The amendment filed</u> ☑ The allowed claim(s) is/are <u>1-4,13,15 and 17</u>. ☑ The drawings filed on <u>05 April 2001</u> are accepted by the Exication Acknowledgment is made of a claim for foreign priority units. 	kaminer.).
a) ☑ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have		
2. Certified copies of the priority documents have	• •	
3. Copies of the certified copies of the priority doc	cuments have been received in t	this national stage application from the
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Acknowledgment is made of a claim for domestic priority ur reference was included in the first sentence of the specifica (a) The translation of the foreign language provisional a Acknowledgment is made of a claim for domestic priority ur in the first sentence of the specification or in an Application	ation or in an Application Data Sl pplication has been received. Inder 35 U.S.C. §§ 120 and/or 12	heet. 37 CFR 1.78.
pplicant has THREE MONTHS FROM THE "MAILING DATE" of elow. Failure to timely comply will result in ABANDONMENT of t		
. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give		
. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing or	on's Patent Drawing Review (P	TO-948) attached s been approved by the Examiner.
(c) ☐ including changes required by the attached Examiner's		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the DEPOSIT OF and/or INFORMATION about the deposit ached Examiner's comment regarding REQUIREMENT FOR The standard control of the standard co	.84(c)) should be written on the dr he margin according to 37 CFR 1. sit of BIOLOGICAL MATERIA	rawings in the front (not the back) of 121(d). AL must be submitted. Note the
ttachm nt(s)	112 321 3311 31 31323 313.12	
☐ Notice of References Cited (PTO-892)	5□ Notice of Informa	al Patent Application (PTO-152)
☐ Notice of Draftperson's Patent Drawing Review (PTO-948)		ary (PTO-413), Paper No
Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No. see below		
☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8☐ Examiner's State 9⊠ Other See Contin	ment of Reasons for Allowance nuation Sheet. JAMES M. SPEAR PRIMARY EXAMINER
		AU 1615

ntinuation of Attachment(s) 9. Other: PTO 1449 filed 12/10/03 & 10/04/01, considered.

JAMES M. SPEAR
PRIMARY EXAMINER

A 4 16 15

Application/Control Number: 09/806,823 Page 2

Art Unit: 1615

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John W. Bailey on January 15, 2004.

IN THE CLAIMS:

Cancel claims 5-12.

2. The following is an examiner's statement of reasons for allowance: Applicants show a quickly disintegrating tablet comprised of a cyclic GMP phosphodiesterase inhibitor and a saccharide. The prior art shows quickly or rapidly disintegrating tablets, such as in JPO Abstract publication number 09048726 A, (applicant's PTO 1449) wherein sugars such as glucose, fructose, sucrose, or a sugar alcohol such as mannitol or sorbitol and a water soluble polymer such as polyvinylpyrrolidone are utilized. The prior art does not show nor fairly suggest applicants' quickly disintegrating tablet or method of making said tablet comprised of a cyclic GMP phosphodiesterase inhibitor in combination with a saccharide selected from the group consisting of mannitol, xylitol, and erythritol wherein the saccharide is present in a ratio of 4 to 30 parts by weight to 1 part by weight of the cyclic GMP phosphodiesterase inhibitor.

Application/Control Number: 09/806,823

Art Unit: 1615

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Claims 1-4, 13, 15 and 17 are allowed.

Claims 5-12, 14 and 16 have been canceled.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James M Spear whose telephone number is 703 308 2457, after February 02, 2004 he may be reached on 703 308 2457. The examiner can normally be reached on Monday thru Friday from 6:30 AM to 3 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page, can be reached on 703 308 2927, after February 03, 2004 he may be reached on 571 272 0602. The fax phone number for the organization where this application or proceeding is assigned is 703 872 9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235.

James M. Spear
Primary Examiner
Art Unit 1615

January 18, 2004